Geopolitical Risk & Brand Reputation

During the peak of the pandemic and its aftermath, the vulnerability of global supply chains highlighted Europe’s critical dependence on non-European countries for producing essential drugs and active ingredients. These supply disruptions endangered public health, economic stability, and the reputation of pharmaceutical companies operating in the sector.

To mitigate these risks, we launched a coordinated initiative to support European companies, raising awareness among Italian, European, and international institutions—including the WHO and major regulatory authorities—about the necessity of relocating pharmaceutical production within the European Union. Our approach focused on an integrated strategy to strengthen local production capabilities, ensuring supply continuity, safeguarding corporate reputations, and reducing external dependency.

Through constant dialogue with key stakeholders and a careful geopolitical risk analysis, we emphasized the strategic advantages of a more resilient European production chain. Furthermore, our initiative encouraged adopting more sustainable production practices aligned with European environmental standards, integrating relocation efforts with innovation and sustainability policies.

The results were significant, increasing institutional awareness and initiating relocation processes that reduced geopolitical risks and enhanced the competitiveness of European pharmaceutical companies, supported by institutional co-investment, incentives, and other strategic instruments.